Evommune, Inc. (NYSE:EVMN – Free Report) – Stock analysts at William Blair issued their Q3 2025 earnings estimates for shares of Evommune in a report issued on Monday, December 1st. William Blair analyst M. Phipps anticipates that the company will post earnings of ($12.16) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Evommune’s Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($3.32) EPS, FY2026 earnings at ($2.35) EPS, FY2027 earnings at ($2.63) EPS, FY2028 earnings at ($2.89) EPS and FY2029 earnings at ($3.89) EPS.
Other analysts also recently issued research reports about the stock. Morgan Stanley began coverage on shares of Evommune in a research report on Monday. They issued an “overweight” rating and a $36.00 price target for the company. Cantor Fitzgerald assumed coverage on Evommune in a research report on Monday. They set an “overweight” rating on the stock. Evercore ISI assumed coverage on Evommune in a research report on Monday. They issued an “outperform” rating and a $40.00 price target for the company. Leerink Partnrs upgraded Evommune to a “strong-buy” rating in a research note on Monday. Finally, Leerink Partners assumed coverage on shares of Evommune in a research note on Monday. They issued an “outperform” rating and a $42.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $39.33.
Evommune Price Performance
NYSE:EVMN opened at $21.97 on Wednesday. Evommune has a 12 month low of $16.70 and a 12 month high of $24.03.
About Evommune
Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions.
Featured Stories
- Five stocks we like better than Evommune
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- The Trade Desk: After a 70% Plunge, This Could Be The Time to Buy
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Tap Into 2026 AI Infrastructure Gains With This High-Growth ETF
- What Are Dividends? Buy the Best Dividend Stocks
- Strong Quarter, Weak Reaction: Why GitLab Shares Dropped
Receive News & Ratings for Evommune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evommune and related companies with MarketBeat.com's FREE daily email newsletter.
